CD274 and neoplasm: The use of multiple proprietary PD-L1 IHC assays, whose comparative outcomes are not well established, and the lack of a clear definition of ‘positive’ tumor-PD-L1 represent a limit for the interpretation of data from clinical trials according to biomarkers [47].